{"id":"hcp1701","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Gastrointestinal disorders"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HCP1701 binds to and activates the glucagon-like peptide-1 (GLP-1) receptor on pancreatic beta cells, stimulating glucose-dependent insulin secretion while simultaneously suppressing glucagon release. The extended half-life formulation allows for less frequent dosing while maintaining sustained metabolic effects on blood glucose regulation.","oneSentence":"HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:14:55.034Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04074551","phase":"PHASE3","title":"A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-07-16","conditions":"Hypertension, Dyslipidemias","enrollment":145},{"nctId":"NCT04322266","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2018-12-21","conditions":"Healthy","enrollment":61}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HCP1701","genericName":"HCP1701","companyName":"Hanmi Pharmaceutical Company Limited","companyId":"hanmi-pharmaceutical-company-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HCP1701 is a long-acting GLP-1 receptor agonist that enhances insulin secretion and reduces glucagon levels to improve glycemic control in diabetes. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}